Formulary guidance and transparency from P&T to point of care


Reality Check on Ophthalmic Anti-Inflammatory

Market access for ophthalmic anti-inflammatory treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, almost 64% and 42% of the lives under commercial formularies and Medicare formularies are covered without utilization management restrictions, respectively
  • Class Trends: In April 2019, Bausch + Lomb announced its launch of Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% in the U.S. for the treatment of postoperative inflammation and pain following ocular surgery 
  • Key Findings: There are numerous products in the ophthalmic anti-inflammatory pipeline; many are new formulations or strengths of the same chemical entity, while only one is a new molecule 

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.